Mehri Çukurcak
Research Subjects
Research Interests
Mehri Çukurcak has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Karakuş
Bartin Universitesi
1 shared publication - Ecem Çitakoğlu
Bartin Universitesi
1 shared publication - Fatma Usta
Bartin Universitesi
1 shared publication - Fatma Özdemi̇r
Bartin Universitesi
1 shared publication - Sevgi Ünal Karakuş
BARTIN ÜNİVERSİTESİ, FEN FAKÜLTESİ, MOLEKÜLER BİYOLOJİ VE GENETİK BÖLÜMÜ
1 shared publication - Sude Aksu
Bartin Universitesi
1 shared publication
Latest Publications
- Open Access
- 15 October 2021
- Published by Trakya University Journal of Natural Sciences in Trakya University Journal of Natural Sciences
- Vol. 22 (2) , 173-177
In vitro CYTOTOXIC EFFECTS OF SOME COVID-19 DRUGS ON LUNG CANCER CELLS
Cancer, which is the second most common cause of death after cardiovascular diseases, is one of the most important health problems of today. Discovery of effective treatments and drugs are important in cancer treatment. The COVID-19 epidemic, which broke out in Wuhan province of China in December 2019 and is considered as a pandemic worldwide, affected millions of people. The SARS-CoV-2 virus, which causes this epidemic, affects the lungs, heart, brain, kidneys, gastrointestinal system, ovaries and testicles and various drugs are used in the treatment. In this study, we aimed to determine the cytotoxic effect of favipiravir, dornase alfa and ivermectin, which are drugs used in the treatment of COVID-19, on human lung cancer cell line (A549). Favipiravir, dornase alfa and ivermectin concentrations were prepared in doubly increasing doses (0.5-64 µg/mL). The prepared concentrations were tested on human A549 cells. After 24 hours of incubation, the cytotoxic effects of the drugs on cancer cells were detected by the MTT (3-(4,5-dimethylthiazol-2-yl)-diphenyl tetrazolium bromide) method. The results were given as % viability. It was determined that favipiravir, dornase alfa and ivermectin significantly decreased the cell viability in lung cancer cell line with increasing application doses (p<0.05).
- 15 October 2021
- Published by Trakya University Journal of Natural Sciences in Trakya University Journal of Natural Sciences
- Vol. 22 (2) , 173-177
Open AccessIn vitro CYTOTOXIC EFFECTS OF SOME COVID-19 DRUGS ON LUNG CANCER CELLS
Cancer, which is the second most common cause of death after cardiovascular diseases, is one of the most important health problems of today. Discovery of effective treatments and drugs are important in cancer treatment. The COVID-19 epidemic, which broke out in Wuhan province of China in December 2019 and is considered as a pandemic worldwide, affected millions of people. The SARS-CoV-2 virus, which causes this epidemic, affects the lungs, heart, brain, kidneys, gastrointestinal system, ovaries and testicles and various drugs are used in the treatment. In this study, we aimed to determine the cytotoxic effect of favipiravir, dornase alfa and ivermectin, which are drugs used in the treatment of COVID-19, on human lung cancer cell line (A549). Favipiravir, dornase alfa and ivermectin concentrations were prepared in doubly increasing doses (0.5-64 µg/mL). The prepared concentrations were tested on human A549 cells. After 24 hours of incubation, the cytotoxic effects of the drugs on cancer cells were detected by the MTT (3-(4,5-dimethylthiazol-2-yl)-diphenyl tetrazolium bromide) method. The results were given as % viability. It was determined that favipiravir, dornase alfa and ivermectin significantly decreased the cell viability in lung cancer cell line with increasing application doses (p<0.05).